新型冠状病毒肺炎、哮喘与吸入性糖皮质激素之间相互作用的多面现实
The polyhedric reality of the interaction between COVID-19, asthma and inhaled corticosteroids.
作者信息
Gonzalez-Barcala Francisco-Javier, Nieto-Fontarigo Juan-Jose, Mendez-Brea Paula, Salgado Francisco-Javier
机构信息
Translational Research In Airway Diseases Group (TRIAD), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
出版信息
ERJ Open Res. 2022 May 30;8(2). doi: 10.1183/23120541.00179-2022. eCollection 2022 Apr.
Abstract
摘要
https://bit.ly/3xLNBrc. （此为网址，无法准确翻译为中文，保留原文即可）
相似文献
1
The polyhedric reality of the interaction between COVID-19, asthma and inhaled corticosteroids.新型冠状病毒肺炎、哮喘与吸入性糖皮质激素之间相互作用的多面现实
ERJ Open Res. 2022 May 30;8(2). doi: 10.1183/23120541.00179-2022. eCollection 2022 Apr.
2
Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience.吸入性糖皮质激素与哮喘患者的 COVID-19 结局：以色列的经验
ERJ Open Res. 2022 Mar 7;8(1). doi: 10.1183/23120541.00014-2022. eCollection 2022 Jan.
3
Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults.在未使用过类固醇的成年持续性哮喘患者中，吸入长效β2受体激动剂联合吸入性类固醇作为一线治疗方案。
Cochrane Database Syst Rev. 2005 Apr 18(2):CD005307. doi: 10.1002/14651858.CD005307.
4
Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma.吸入长效β2受体激动剂与吸入性糖皮质激素联合使用与高剂量吸入性糖皮质激素治疗儿童和成人持续性哮喘的比较
Cochrane Database Syst Rev. 2005 Oct 19(4):CD005533. doi: 10.1002/14651858.CD005533.
5
Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth.持续性哮喘儿童吸入糖皮质激素：对生长的剂量反应效应
Evid Based Child Health. 2014 Dec;9(4):931-1046. doi: 10.1002/ebch.1989.
6
Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.沙美特罗和吸入性类固醇用于慢性哮喘的常规治疗：严重不良事件
Cochrane Database Syst Rev. 2013 Mar 28(3):CD006922. doi: 10.1002/14651858.CD006922.pub3.
7
Inhaled corticosteroids in children with persistent asthma: effects on growth.吸入性糖皮质激素对持续性哮喘儿童生长发育的影响
Evid Based Child Health. 2014 Dec;9(4):829-930. doi: 10.1002/ebch.1988.
8
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.福莫特罗与布地奈德联合用于成人和儿童慢性哮喘的维持和缓解治疗与当前最佳实践（包括吸入性糖皮质激素维持治疗）的对比研究
Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD007313. doi: 10.1002/14651858.CD007313.pub3.
9
Does inhaled corticosteroid use affect the risk of
COVID-19-related death?吸入性糖皮质激素的使用是否会影响与COVID-19相关的死亡风险？
Breathe (Sheff). 2021 Mar;17(1):200275. doi: 10.1183/20734735.0275-2020.
10
Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.长效β2受体激动剂与抗白三烯药物联合吸入糖皮质激素治疗慢性哮喘的比较
Cochrane Database Syst Rev. 2011 May 11(5):CD003137. doi: 10.1002/14651858.CD003137.pub4.
引用本文的文献
1
Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study.COVID-19 感染住院患者吸入环索奈德的临床获益：一项回顾性研究。
BMC Pulm Med. 2022 Sep 28;22(1):368. doi: 10.1186/s12890-022-02168-8.
2
Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain.新冠疫苗加强针在普通人群和合并症患者中的效果。西班牙的一项基于人群的研究。
Environ Res. 2022 Dec;215(Pt 2):114252. doi: 10.1016/j.envres.2022.114252. Epub 2022 Sep 10.
本文引用的文献
1
Risk Factors of Mortality in Hospitalized Patients With COVID-19 Applying a Machine Learning Algorithm.应用机器学习算法分析新型冠状病毒肺炎住院患者的死亡风险因素
Open Respir Arch. 2022 Feb 6;4(2):100162. doi: 10.1016/j.opresp.2022.100162. eCollection 2022 Apr-Jun.
2
Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience.吸入性糖皮质激素与哮喘患者的 COVID-19 结局：以色列的经验
ERJ Open Res. 2022 Mar 7;8(1). doi: 10.1183/23120541.00014-2022. eCollection 2022 Jan.
3
Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study.国际严重急性呼吸和新发感染联盟WHO临床特征方案中登记的重症新型冠状病毒肺炎患者的临床特征、危险因素及预后：一项前瞻性、多国、多中心观察性研究
ERJ Open Res. 2022 Feb 14;8(1). doi: 10.1183/23120541.00552-2021. eCollection 2022 Jan.
4
Is asthma associated with COVID-19 infection? A UK Biobank analysis.哮喘与新冠病毒感染有关联吗？一项英国生物银行分析。
ERJ Open Res. 2021 Nov 29;7(4). doi: 10.1183/23120541.00309-2021. eCollection 2021 Oct.
5
The relationship of asthma severity to COVID-19 outcomes.哮喘严重程度与新冠病毒病结局的关系。
J Allergy Clin Immunol Pract. 2022 Jan;10(1):318-321.e2. doi: 10.1016/j.jaip.2021.10.041. Epub 2021 Oct 27.
6
Asthma in older adults with severe coronavirus disease 2019: Clinical outcomes and predictors of mortality.患有严重2019冠状病毒病的老年人的哮喘：临床结局和死亡率预测因素。
Ann Allergy Asthma Immunol. 2022 Feb;128(2):213-215. doi: 10.1016/j.anai.2021.10.016. Epub 2021 Oct 17.
7
Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases.新冠肺炎合并既往肺部疾病住院患者的患病率及30天死亡率
Arch Bronconeumol. 2021 Apr;57:13-20. doi: 10.1016/j.arbres.2020.11.012. Epub 2020 Dec 16.
8
Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map.西班牙用于重度难治性哮喘的单克隆抗体治疗：分析图谱。
J Asthma. 2022 Oct;59(10):1997-2007. doi: 10.1080/02770903.2021.1978483. Epub 2021 Sep 17.
9
Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19.新型冠状病毒肺炎患者中哮喘表型、相关共病和长期症状。
Allergy. 2022 Jan;77(1):173-185. doi: 10.1111/all.14972. Epub 2021 Jun 19.
10
Recovery from COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group members.新冠康复：短跑还是马拉松？来自线上新冠长期症状支持小组成员的6个月随访数据。
ERJ Open Res. 2021 May 24;7(2). doi: 10.1183/23120541.00141-2021. eCollection 2021 Apr.
Zotero 插件